Reviva Pharmaceuticals Holdings Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
14
- Stock Symbol
-
RVPH
- Investments
-
1
- Share Price
-
$0.35
- (As of Monday Closing)
Reviva Pharmaceuticals Holdings General Information
Description
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
Contact Information
Website
www.revivapharma.comCorporate Office
- 10080 North Wolfe Road
- Suite SW3-200
- Cupertino, CA 95014
- United States
Corporate Office
- 10080 North Wolfe Road
- Suite SW3-200
- Cupertino, CA 95014
- United States
Reviva Pharmaceuticals Holdings Stock Performance
As of 16-Nov-2026, Reviva Pharmaceuticals Holdings’s stock price is $0.35. Its current market cap is $4.59M with 13.1M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.35 | $0.35 | $0.26 - $15.40 | $4.59M | 13.1M | 29.7K | -$0.48 |
Reviva Pharmaceuticals Holdings Financials Summary
As of 30-Sep-2026, Reviva Pharmaceuticals Holdings has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (13,584) | 19,418 | 78,832 | 139,031 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (11,839) | (20,144) | (30,242) | (39,609) |
| Net Income | (11,310) | (19,865) | (29,919) | (39,261) |
| Total Assets | 18,557 | 15,923 | 15,503 | 23,700 |
| Total Debt | 44 | 407 | 458 | 0 |
Reviva Pharmaceuticals Holdings Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Reviva Pharmaceuticals Holdings Comparisons
Industry
Financing
Details
Reviva Pharmaceuticals Holdings Competitors (5)
One of Reviva Pharmaceuticals Holdings’s 5 competitors is Praxis (Drug Discovery), a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Praxis (Drug Discovery) | Formerly VC-backed | Boston, MA | ||||
| Vanda Pharmaceuticals | Formerly VC-backed | Washington, DC | ||||
| Axsome Therapeutics | Formerly VC-backed | New York, NY | ||||
| Alkermes | Formerly VC-backed | Dublin, Ireland | ||||
| Definium Therapeutics | Formerly VC-backed | New York, NY |
Reviva Pharmaceuticals Holdings Patents
Reviva Pharmaceuticals Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026136179-A1 | Method for treating negative symptoms of schizophrenia | Pending | 16-Dec-2024 | ||
| EP-4687910-A1 | Brilaroxazine liposome composition | Pending | 30-Mar-2023 | ||
| US-20260021104-A1 | Brilaroxazine liposome composition | Pending | 30-Mar-2023 | ||
| WO-2024206692-A1 | Brilaroxazine liposome composition | Inactive | 30-Mar-2023 | ||
| EP-4687911-A1 | Method for treating psoriasis | Pending | 30-Mar-2023 | A61K31/538 |
Reviva Pharmaceuticals Holdings Signals
Reviva Pharmaceuticals Holdings Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Reviva Pharmaceuticals Holdings Acquisitions (1)
Reviva Pharmaceuticals Holdings’s most recent deal was a Merger/Acquisition with Tenzing Acquisition. The deal was made on 14-Dec-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tenzing Acquisition | 14-Dec-2020 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Reviva Pharmaceuticals Holdings ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Reviva Pharmaceuticals Holdings FAQs
-
When was Reviva Pharmaceuticals Holdings founded?
Reviva Pharmaceuticals Holdings was founded in 2006.
-
Where is Reviva Pharmaceuticals Holdings headquartered?
Reviva Pharmaceuticals Holdings is headquartered in Cupertino, CA.
-
What is the size of Reviva Pharmaceuticals Holdings?
Reviva Pharmaceuticals Holdings has 14 total employees.
-
What industry is Reviva Pharmaceuticals Holdings in?
Reviva Pharmaceuticals Holdings’s primary industry is Drug Discovery.
-
Is Reviva Pharmaceuticals Holdings a private or public company?
Reviva Pharmaceuticals Holdings is a Public company.
-
What is Reviva Pharmaceuticals Holdings’s stock symbol?
The ticker symbol for Reviva Pharmaceuticals Holdings is RVPH.
-
What is the current stock price of Reviva Pharmaceuticals Holdings?
As of 16-Nov-2026 the stock price of Reviva Pharmaceuticals Holdings is $0.35.
-
What is the current market cap of Reviva Pharmaceuticals Holdings?
The current market capitalization of Reviva Pharmaceuticals Holdings is $4.59M.
-
Who are Reviva Pharmaceuticals Holdings’s competitors?
Praxis (Drug Discovery), Vanda Pharmaceuticals, Axsome Therapeutics, Alkermes, and Definium Therapeutics are competitors of Reviva Pharmaceuticals Holdings.
-
What is Reviva Pharmaceuticals Holdings’s annual earnings per share (EPS)?
Reviva Pharmaceuticals Holdings’s EPS for 12 months was -$0.48.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process